API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga® (abiraterone acetate), is an anticancer medication. It works by preventing androgen (male hormone) production in man.
Lead Product(s): Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Abiraterone Acetate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2020
Details:
Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.
Lead Product(s): Abiraterone Acetate,Prednisolone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
KPG-121 is a modulator of the CRL4CRBN complex targeting rapid ubiquitination and degradation of CK1 alpha, IKZF3 and IKZF1. It is being investigated in combination with Abiraterone for mCRPC.
Lead Product(s): Lenalidomide Analog,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: KPG-121
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2024
Details:
Under the agreement, Novartis obtains worldwide development and commercialization rights of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer and also its preclinical AR-V7 program.
Lead Product(s): Luxdegalutamide,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: ARV-766
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,160.0 million Upfront Cash: $150.0 million
Deal Type: Licensing Agreement April 11, 2024
Details:
JNJ-64091742 (niraparib) is an orally administered, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor that is currently being studied for the treatment of metastatic castrationresistant prostate cancer with BRCA alterations.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: JNJ-64091742
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2023
Details:
Lynparza (olaparib) is a first-in-class PARP inhibitor and approved in combination with abiraterone for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.
Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
USFDA approves FoundationOne®CDx to be used as a companion diagnostic for AKEEGA (niraparib and abiraterone acetate), the first-and-only dual action tablet, which was approved for deleterious BRCA-mutated metastatic castration-resistant prostate cancer in adults.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Akeega
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2023
Details:
KEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, for the treatment of adult patients with BRCA-positive mCRPC.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Akeega
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2023
Details:
Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment which leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.
Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
Lynparza (olaparib), a first-in-class PARP inhibitor, gets FDA approval for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer. It is already approved in the US for HRR gene-mutated mCRPC.
Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
Lynparza® (olaparib), PARP inhibitor, in combination with abiraterone (an androgen biosynthesis inhibitor) and prednisone or prednisolone is being investigated in BRCA-mutated metastatic castration-resistant prostate cancer.
Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2023
Details:
Akeega is a combination of niraparib, a highly selective poly (ADP ribose) polymerase (PARP) inhibitor and abiraterone acetate, an androgen biosynthesis inhibitor is being studied for adult patients with BRCA1/2 gene mutated metastatic castration resistant prostate cancer.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Akeega
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2023
Details:
ESSA will conduct a Phase 1 trial evaluating the safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumor activity of EPI-7386 when administered in combination with either apalutamide or abiraterone acetate plus prednisone in patients with prostate cancer.
Lead Product(s): Masofaniten,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 12, 2023
Details:
Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment which leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.
Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment which leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.
Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Details:
JNJ-64091742 is a combination of niraparib, an orally administered, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor and abiraterone acetate, an androgen biosynthesis inhibitor, is currently being studied for the treatment of prostate cancer.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: JNJ-64091742
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Akeega is a combination of niraparib, a highly selective poly (ADP ribose) polymerase (PARP) inhibitor and abiraterone acetate, an androgen biosynthesis inhibitor is being studied for adult patients with BRCA1/2 gene mutated metastatic castration resistant prostate cancer.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Akeega
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2023
Details:
TAVT-45 (abiraterone acetate) Granules for Oral Suspension (“TAVT-45”), is an enhanced formulation of abiraterone acetate for the treatment of metastatic prostate cancer. Abiraterone inhibits testosterone production, which can suppress tumor growth.
Lead Product(s): Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: TAVT-45
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
Abiraterone acetate is a medication used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.
Lead Product(s): Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Abiraterone Acetate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 04, 2023
Details:
LYNPARZA (olaparib) in combination with abiraterone and prednisone or prednisolone reduced the risk of disease progression or death by 34% (HR=0.66 [95% CI, 0.54-0.81]; p<0.0001) versus placebo plus abiraterone and prednisone or prednisolone, based on investigator assessment.
Lead Product(s): Olaparib,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency in HRR, such as those with mutations in BRCA1 and/or BRCA2, or those where deficiency is induced by other agents.
Lead Product(s): Olaparib,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
LYNPARZA (olaparib), is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.
Lead Product(s): Olaparib,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
Lynparza (olaparib) is first-in-class PARP inhibitor and first targeted treatment to block DNA damage response in cells/tumours harboring deficiency in HRR.
Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
LYNPARZA (Olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.
Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor. EPI-7386 is being studied in men with castration-resistant prostate cancer ("CRPC") whose tumors have progressed on standard-of-care therapies.
Lead Product(s): Masofaniten,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
The safety and tolerability of LYNPARZA (olaparib) in combination with abiraterone and prednisone or prednisolone was in line with that observed in prior clinical trials and the known proles of the individual medicines.
Lead Product(s): Olaparib,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2022
Details:
Abiraterone acetate 250 mg is indicated in combination with prednisone for the treatment of people with metastatic castration-resistant prostate cancer (CRPC) and those with metastatic high-risk castration-sensitive prostate cancer (CSPC).
Lead Product(s): Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Abiraterone Acetate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
TAVT-45 is designed to provide an easy-to-consume oral suspension of abiraterone acetate, reconstituted in water or juice, for patients with difficulty taking large tablets.
Lead Product(s): Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: TAVT-45
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Results showed that LYNPARZA (olaparib) in combination with abiraterone plus prednisone signicantly improved radiographic progression-free survival v/s abiraterone plus prednisone, as rest-line treatment for patients with metastatic castration-resistant prostate cancer.
Lead Product(s): Olaparib,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
Fujovee (abivertinib) is a novel small molecule tyrosine kinase inhibitor that selectively targets both mutant forms of epidermal growth factor receptor as well as Bruton's tyrosine kinase and has been shown to inhibit extragonadal androgen production in preclinical models.
Lead Product(s): Abivertinib,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Fujovee
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
The submission to the European Medicines Agency is based on results from the Phase 3 MAGNITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone for the treatment of patients with mCRPC who are positive for HRR gene alterations.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Zejula
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
Niraparib is an orally administered, selective poly-ADP ribose polymerase (PARP) inhibitor, that is currently being studied by Janssen for the treatment of patients with prostate cancer.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: JNJ-64091742
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
The safety and tolerability of Lynparza in combination with abiraterone was in line with that observed in prior clinical trials and the known profiles of the individual medicines.
Lead Product(s): Olaparib,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
Positive results from Phase 3 PROpel trial showed LYNPARZA in combination with abiraterone plus prednisone demonstrated a statistically significant and clinically meaningful improvement in rPFS, versus abiraterone plus prednisone for treatment of patients with mCRPC.
Lead Product(s): Olaparib,Abiraterone Acetate,Prednisolone
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
Niraparib is an orally administered, poly-ADP ribose polymerase inhibitor that is currently studied for the treatment of prostate cancer. ERLEADA (apalutamide), an androgen receptor inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Zejula
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2022
Details:
Initial results from Phase 3 MAGNITUDE study of niraparib in combination with abiraterone acetate plus prednisone as a first-line therapy in patients with metastatic castration-resistant prostate cancer featured as an oral presentation.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Zejula
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2022
Details:
Cirtuvivint is a small-molecule inhibitor of the CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases that are emerging as key contributors to numerous forms of cancer.
Lead Product(s): Cirtuvivint,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: SM08502
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2021
Details:
The ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); however, combination treatment did not show significant benefit over the active control ZYTIGA® plus prednisone in key secondary endpoints, including overall survival (OS).
Lead Product(s): Apalutamide,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Erleada
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2021
Details:
ACIS was a Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical study evaluating the efficacy and safety of ERLEADA and ZYTIGA plus prednisone compared to placebo and ZYTIGA plus prednisone in 982 patients with chemotherapy-naïve mCRPC who received ADT.
Lead Product(s): Apalutamide,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Erleada
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2021
Details:
Two-fold increase (29% to 63%) in disease control rate at 12 weeks (the trial's primary efficacy endpoint) seen in patients receiving onvansertib for 14 days vs. 5 days in a 21-day cycle.
Lead Product(s): Onvansertib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Onvansertib
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2021
Details:
Data from the ACIS study showed a meaningful increase in rPFS in evaluating the combination of apalutamide and abiraterone acetate plus prednisone in the treatment of metastatic castration-resistant prostate cancer.
Lead Product(s): Apalutamide,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: JNJ-56021927
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2021
Details:
The ANDA is approved for its use in combination with Prednisone. Abiraterone Acetate Tablets, USP, 250 mg and 500 mg, are the generic version of Zytiga® for treatment of metastatic prostate cancer.
Lead Product(s): Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2021
Details:
Safety demonstrated across all three dose/dose scheduling cohorts, including cohort C with onvansertib dosed over a longer period of time than cohorts A and B (onvansertib on Days 1 - 14 in a 21-day cycle).
Lead Product(s): Onvansertib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: PCM-075
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
Pre-clinical trials by the University of South Australia of abiraterone acetate show the new formulation improves the drug's effectiveness by 40 per cent.
Lead Product(s): Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Zytiga
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2020
Details:
Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care plus placebo met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with PTEN loss tumors.
Lead Product(s): Ipatasertib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2020
Details:
Onvansertib demonstrates efficacy in Zytiga®-resistant metastatic castration-resistant prostate cancer (mCRPC) across known androgen receptor resistance mechanisms.
Lead Product(s): Onvansertib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2020
Details:
Under the agreement, both companies will start co-promoting ZYTIGA® to healthcare professionals in Japan from March 2, 2020, with Janssen retaining marketing authorization for ZYTIGA®.
Lead Product(s): Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Janssen Pharmaceutical K.K.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 07, 2020